Markus Cornberg,Michael P Manns
Markus Cornberg
The development of direct-acting antivirals (DAA) has revolutionized the treatment of chronic hepatitis C, enabling cure of hepatitis C virus (HCV) infection in more than 95% of cases. There are essentially no contraindications, so almost a...
Case study of hepatitis C virus control in Egypt: impact of access program [0.03%]
埃及乙肝病毒控制案例研究：获取方案的影响
Imam Waked
Imam Waked
Background: Although Egypt was the country with the highest prevalence of hepatitis C in the world, the availability of sofosbuvir based therapies enabled Egypt to be the first country to eliminate hepatitis C and cure mo...
Virus reactivation in a non-cirrhotic HBV patient requiring liver transplantation after cessation of nucleoside analogue therapy [0.03%]
乙型肝炎患者停用核苷类似物后需进行肝脏移植的病毒再活化
Han Zhang,Fang Chen,Erick Giang et al.
Han Zhang et al.
Nucleos(t)ide analogues (NAs) are a mainstay of therapy for chronic hepatitis B (CHB) infections and have a profound effect on hepatitis B virus (HBV) suppression. We report a rare case of HBV reactivation in a CHB patient without cirrhosis...
Pharmacokinetics, safety and tolerability of single- and multiple-ascending doses of JNJ-64530440, a novel hepatitis B virus capsid assembly modulator, in healthy volunteers [0.03%]
JNJ-64530440的药代动力学、安全性和耐受性：一种新型乙型肝炎病毒衣壳装配调节剂在健康志愿者中的剂量递增研究
Thomas N Kakuda,Jeysen Z Yogaratnam,Christopher Westland et al.
Thomas N Kakuda et al.
Background: Pharmacokinetics and safety of JNJ-64530440, a hepatitis B virus capsid assembly modulator producing normal empty capsids (CAM-N), in healthy volunteers were evaluated. ...
Clinical Trial
Antiviral therapy. 2021 Jan-Feb;26(1-2):13-24. DOI:10.1177/13596535211044331 2021
Comparative outcomes of lopinavir/ritonavir and hydroxychloroquine for the treatment of COVID-19 with mild-to-moderate severity: A retrospective observational study [0.03%]
治疗轻至中度COVID-19患者接受洛匹那韦/利托那韦与羟氯喹的结局比较：一项回顾性观察研究
Jeong Eun Lee,Soon Ok Lee,Jeonghun Heo et al.
Jeong Eun Lee et al.
Background: Lopinavir/ritonavir (LPV/r) and hydroxychloroquine (HCQ) are both being used to treat coronavirus disease 2019 (COVID-19), but their relative effectiveness is unknown. The purpose of this study was to compare ...
Observational Study
Antiviral therapy. 2021 Jan-Feb;26(1-2):34-42. DOI:10.1177/13596535211039394 2021
Higher risk of mortality in HIV-HBV co-infected patients from sub-Saharan Africa is observed at lower CD4+ cell counts [0.03%]
观察到在较低CD4+细胞计数时，来自东非的HIV-HBV合并感染患者的死亡风险更高
Gérard M Kouamé,Delphine Gabillard,Raoul Moh et al.
Gérard M Kouamé et al.
Background: Hepatitis B virus (HBV) co-infection in human immunodeficiency virus (HIV)-positive individuals increases the risk of overall mortality, especially when HBV DNA levels are high. The role of CD4+ cell counts in...
Randomized Controlled Trial
Antiviral therapy. 2021 Jan-Feb;26(1-2):25-33. DOI:10.1177/13596535211039589 2021
Antiviral effect of Artemisia aucheri aqueous extract on UL46 and US6 genes of HSV-1 [0.03%]
艾草对HSV-1的UL46和US6基因的抗病毒作用
Mahsa Zamanian,Zohreh Sharifi,Zahra Noormohammadi et al.
Mahsa Zamanian et al.
HSV-1 is associated with oral lesions. Recently, anti-herpetic activity of different plant species has been investigated. In this study, the effects of Artemisia aucheri aqueous extract on the HSV-1 virus-infected Vero cells were assessed. ...
An unexpected adverse effect: Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide-induced cholestasis [0.03%]
意外的不良反应：艾维格韦/库比西特韦/恩曲他滨/替诺福韦阿拉芬酰胺引起的胆汁淤积
Ainoa Ugarte,Lorena De la Mora,María Martínez-Rebollar et al.
Ainoa Ugarte et al.
Long-term safety and efficacy of rilpivirine in combination with nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 336-week rollover study of phase 2b and 3 clinical studies [0.03%]
利匹韦林联合核苷/核苷酸逆转录酶抑制剂治疗HIV-1感染者长期安全性和疗效：2b期和3期临床研究的336周扩展研究
Jean Michel Molina,Luminita Ene,Pedro Cahn et al.
Jean Michel Molina et al.
Background: To evaluate the long-term safety and efficacy of rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), in combination with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) ...
Clinical Trial
Antiviral therapy. 2021 Nov;26(6-8):95-105. DOI:10.1177/13596535211062388 2021
HBV co-infection is associated with persistently elevated liver stiffness measurement in HIV-positive adults: A 6-year single-centre cohort study in Nigeria [0.03%]
尼日利亚成人HIV患者中乙肝病毒感染与肝脏硬度持续升高相关：一项为期六年的单中心队列研究
Adovich S Rivera,Stephen Machenry,Jonathan Okpokwu et al.
Adovich S Rivera et al.
Background: In Nigeria, the effect of Hepatitis B virus (HBV) on long-term liver outcomes in persons with HIV (PLH) has not been described. We determined changes in liver stiffness measure (LSM) using transient elastograp...